Company cuts 9,000 jobs and lowers profit forecast as Wegovy sales slow. Q3 operating profit down 30% on competition ...

Scientists are investigating whether popular weight-loss drugs like Ozempic could influence fertility or interfere with birth ...

SmartScripts has faced a welter of lawsuits and been fined for its sale of a counterfeit version of popular weight-loss drug Ozempic.

The Danish pharmaceutical giant Novo Nordisk has struck an agreement with the Centers for Medicare & Medicaid Services (CMS) ...

Dow Jones Top Company Headlines at 7 AM ET: Humana Cuts Earnings Outlook as Medical Costs Surge | Bunge ... Humana reported lower third-quarter profit and slashed full-year earnings guidance as ...

Novo Nordisk Q3 profit drops on restructuring costs as GLP-1 and obesity drug sales rise; company narrows 2025 growth outlook.

Denmark's Novo Nordisk, the maker of Ozempic and Wegovy obesity drugs, said on Wednesday it was lowering its 2025 outlook for the third time this year, after posting tepid third-quarter results.

LONDON (Reuters) -Novo Nordisk said on Wednesday it had agreed a price under the U.S. Medicare scheme for semaglutide, the ...

The latest of those is a bid valued at up to $10 billion for U.S. obesity-drug developer Metsera, up from a previous $9 billion offer it originally made, as it tries to usurp an already agree-on deal ...

Novo Nordisk said on Wednesday it has accepted the U.S. Inflation Reduction Act (IRA)'s maximum fair price for its diabetes ...

Novo launched a rival bid to acquire American obesity biotech firm Metsera last week, superseding an offer for the firm from ...

Intensifying competition, pricing pressure and copycat versions of Ozempic and Wegovy hold back sales at the pharma giant.